In January 1991, four enterprises—Nanning Pharmaceutical Factory, Nanning Pharmaceutical Factory No. 2, Nanning Traditional Chinese Medicine Factory, and Nanning Architectural Decoration Materials Factory—merged and restructured to form the Nanning Pharmaceutical Enterprise Group Company of the Guangxi Zhuang Autonomous Region, which became a large-scale, second-tier state-owned enterprise.

In September 2000, the company was restructured and renamed Guangxi Nanning Baihui Pharmaceutical Group Co., Ltd.;

In May 2014, "Baihui Pharmaceutical" was wholly owned and operated by Guangxi Fengye Investment Co., Ltd.

Currently, all production facilities at "Baihui Pharmaceutical" have successfully passed GMP certification. The company boasts a comprehensive product portfolio, featuring a pharmaceutical production system that is anchored in essential medicines while highlighting the unique characteristics of "Zhuang medicine." It produces 14 dosage forms—ranging from tablets and capsules to granules, powders, syrups, oral solutions, oral suspensions, gels, mixtures, lozenges, small-volume injections, and even active pharmaceutical ingredients—comprising a total of 244 distinct product varieties. Among these, 72 varieties are listed in the 2018 National Essential Medicines List, 10 are included in the 2012 Guangxi Supplementary Essential Medicines List, 144 are covered by the National Medical Insurance Program, and 166 fall under Guangxi’s local medical insurance scheme. The company’s products cater to a wide range of therapeutic areas, including digestive health, cardiovascular and cerebrovascular conditions, orthopedics, respiratory care, pediatric treatments, and health supplements. With a well-balanced product lineup and consistently high-quality standards, Baihui Pharmaceutical has earned the trust of patients nationwide. Additionally, several of its flagship products, such as Glucose Injection and Inosine Oral Solution, have been recognized as prestigious brand-name products by the Guangxi Zhuang Autonomous Region.

"Baihui Pharmaceutical" boasts strong independent R&D capabilities, having established both the Guangxi Zhuang Autonomous Region-level Technology Center—Guangxi Baihui Pharmaceutical Drug Research Institute—and the National "Zhuanggu 3131 Engineering Center Zhuang Medicine Modernization Research Center." Over the years, the company has secured a total of 16 patents and earned 9 new drug certificates. For many years, Baihui Pharmaceutical has steadfastly pursued a path of technological innovation, continuously strengthening its ability to foster independent innovation while leveraging technological advancements and product development to drive business growth. In recent years, the company has independently developed 10 nationally recognized new drugs, including Magnesium Aluminum Carbonate Suspension, Jian Gu Injection, Compound Fresh Dendrobium Granules, Hair Growth Tablets, and Qu Feng Tong Tablets—each of which represents a national first. Among these, Jian Gu Injection and Compound Fresh Dendrobium Granules were among the first to apply for national patents back in 1994, with the Fresh Dendrobium Granules later receiving an invention patent certificate in 2000. In recent years, through dedicated efforts in independent innovation, Baihui Pharmaceutical has successfully completed production applications for two Class 5 chemical drugs: Acetyl Kitasamycin Dispersible Tablets and Compound Glycyrrhizin Sodium Chloride Injection—as well as for a Class 6 chemical drug, Xylitol Injection. Notably, both Acetyl Kitasamycin Dispersible Tablets and Compound Glycyrrhizin Sodium Chloride Injection have been designated as Nanning City's innovative technology projects. The company currently holds 28 registered trademarks, including "Baihui," "Ted," and "Kanglilong," with "Baihui" proudly recognized as a renowned trademark in Guangxi Province. In 2014, Baihui Pharmaceutical was jointly awarded the title of "High-Tech Enterprise" by Guangxi’s Department of Science and Technology, Department of Finance, State Taxation Administration, and Local Taxation Administration. The company was again honored as a "High-Tech Enterprise" in 2018 and has also received prestigious accolades such as "National Top 100 Enterprises Specializing in Ethnic Trade and Ethnic-Specific Products," bestowed by relevant departments under the State Ethnic Affairs Commission.

"Baihui Pharmaceutical" has been repeatedly recognized as an advanced unit (enterprise) in Nanning City, earning the city’s prestigious “Gold Cup Award,” “Silver Cup Award,” and “Bronze Cup Award” for economic performance. Additionally, it has been honored as one of Nanning City’s “Top 10” tax-paying enterprises, a standout contributor to tax payments, and a company consistently praised for honoring contracts and maintaining high business integrity. The company is also designated as an enterprise in a nationally encouraged industry.

In 2014, to achieve the company's strategic growth and build a modern pharmaceutical enterprise, "Baihui Pharmaceutical" secured new land—150 mu at No. 39 Jinyang Road—in the Nanning National Economic and Technological Development Zone, thanks to the care and support from governments at various levels in the autonomous region and Nanning City. This marked the start of construction on the company's new factory project.

"Baihui Pharmaceutical" boasts strong independent R&D capabilities, having established both the Guangxi Zhuang Autonomous Region-level Technology Center—Guangxi Baihui Pharmaceutical Drug Research Institute—and the National "Zhuanggu 3131 Engineering Center Zhuang Medicine Modernization Research Center." Over the years, the company has secured a total of 16 patents and earned 9 new drug certificates. Committed to advancing through technological innovation, Baihui Pharmaceutical has consistently focused on strengthening its ability to foster independent innovation, leveraging technological advancements and product development to drive business growth. In recent years, the company has independently developed 10 nationally recognized new drugs, including Magnesium Aluminum Carbonate Suspension, JianGu Injection, Compound Fresh Dendrobium Granules, Hair Growth Tablets, and Qu Feng Tong Tablets—each representing groundbreaking innovations nationwide. Among these, JianGu Injection and Compound Fresh Dendrobium Granules were first patented at the national level in 1994, while Fresh Dendrobium Granules received an invention patent certificate in 2000. In recent years, through dedicated efforts in independent innovation, Baihui Pharmaceutical has successfully completed production applications for two Class 5 chemical drugs: Acetyl Kitasamycin Dispersible Tablets and Compound Glycyrrhizin Sodium Chloride Injection. Additionally, the company has initiated production filings for another Class 6 chemical drug—Xylitol Injection. Notably, Acetyl Kitasamycin Dispersible Tablets and Compound Glycyrrhizin Sodium Chloride Injection have been designated as Nanning City's innovative technology projects. The company proudly holds 28 registered trademarks, including "Baihui," "Ted," and "Kanglilong," with "Baihui" recognized as a renowned trademark in Guangxi Province.